Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence With Imetelstat In IMerge Phase 3 Lower Risk MDS Patients
Portfolio Pulse from Happy Mohamed
Geron Corporation announced positive results from its IMerge Phase 3 trial of imetelstat in lower risk MDS patients at the ASCO Annual Meeting. The primary endpoint of 8-week transfusion independence was met with high statistical significance, and the data supports an NDA submission planned for June 2023.
June 02, 2023 | 7:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron's imetelstat demonstrated positive results in the IMerge Phase 3 trial, meeting the primary endpoint of 8-week transfusion independence. The data supports an NDA submission planned for June 2023.
The positive results from the IMerge Phase 3 trial indicate that imetelstat has the potential to be a successful treatment for lower risk MDS patients. This is likely to have a positive impact on Geron's stock price in the short term, as it supports the planned NDA submission in June 2023 and potential commercial launch in the first half of 2024.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100